Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in ...
Grace Therapeutics, Inc. (NASDAQ: GRCE) is a late-stage biopharmaceutical company headquartered in Princeton, New Jersey, with operations centered in Canada. Originally incorporated in 2002 as Acasti Pharma Inc., the company rebranded to Grace Therapeutics in October 2024 to reflect its scientific heritage. The company specializes in creating and commercializing pharmaceutical ...Grace Therapeutics, Inc. (NASDAQ: GRCE) is a late-stage biopharmaceutical company headquartered in Princeton, New Jersey, with operations centered in Canada. Originally incorporated in 2002 as Acasti Pharma Inc., the company rebranded to Grace Therapeutics in October 2024 to reflect its scientific heritage. The company specializes in creating and commercializing pharmaceutical products for rare and orphan diseases, leveraging novel drug delivery technologies to improve the performance of existing drugs. Its most advanced candidate, GTX-104, is an intravenous infusion for subarachnoid hemorrhage, which has completed Phase 3 trials. Other pipeline assets include GTX-102, an oral mucosal betamethasone spray for ataxia-telangiectasia, and GTX-101, a topical bioadhesive bupivacaine spray for postherpetic neuralgia. The company has received Orphan Drug Designation from the FDA for its clinical assets, providing seven years of marketing exclusivity in the U.S. Grace Therapeutics is led by CEO Prashant Kohli, who has over 20 years of commercialization experience, and is backed by founders including George Kottayil and Dr. Kavuru. As of the latest fiscal year, the company reported a net loss of $7.8 million, with $17 million in cash and cash equivalents. With a small team of around 5 employees, the company is focused on advancing its pipeline and preparing for potential commercialization. Financial metrics indicate a strong current ratio, low debt, and an enterprise value of $17.5 million. The company is traded on the NASDAQ Global Market and continues to develop therapies for unmet medical needs in rare diseases.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-7.8M
+42.8%
-1240.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-8.9M
+40.5%
-88.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
—
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
8.10x
-31.2%
+41.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
